SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics - Quaterly Results

08 Aug 2022 Evaluate
The sales for the June 2022 quarter moved down to Rs. 288.79 millions as compared to Rs. 360.66 millions during the year-ago period.The Net Loss for the quarter ended June 2022 is Rs. -120.84 millions as compared to Net Profit of Rs. 8.06 millions of corresponding quarter ended June 2021Operating profit Margin for the quarter ended June 2022 slipped to -81.19% as compared to 46.42% of corresponding quarter ended June 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 288.79 360.66 -19.93 288.79 360.66 -19.93 1371.27 2023.80 -32.24
Other Income 0.09 0.15 -40.00 0.09 0.15 -40.00 0.57 0.58 -1.72
PBIDT -81.19 46.42 -274.90 -81.19 46.42 -274.90 156.89 472.79 -66.82
Interest 0.09 0.28 -67.86 0.09 0.28 -67.86 0.40 19.63 -97.96
PBDT -81.28 46.14 -276.16 -81.28 46.14 -276.16 77.89 453.16 -82.81
Depreciation 30.66 34.71 -11.67 30.66 34.71 -11.67 139.99 158.24 -11.53
PBT -111.94 11.43 -1079.35 -111.94 11.43 -1079.35 -62.10 294.92 -121.06
TAX 8.90 3.37 164.09 8.90 3.37 164.09 -8.42 67.14 -112.54
Deferred Tax 8.90 -0.84 -1159.52 8.90 -0.84 -1159.52 -14.62 56.47 -125.89
PAT -120.84 8.06 -1599.26 -120.84 8.06 -1599.26 -53.68 227.78 -123.57
Equity 406.73 406.73 0.00 406.73 406.73 0.00 406.73 406.73 0.00
PBIDTM(%) -28.11 12.87 -318.43 -28.11 12.87 -318.43 11.44 23.36 -51.03

Lasa Supergenerics Share Price

8.14 0.25 (3.17%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×